Research Article

The effect of miR-640 on metastatic genes in breast cancer

Volume: 65 Number: 1 March 9, 2026
EN TR

The effect of miR-640 on metastatic genes in breast cancer

Abstract

Aim: Despite the implementation of numerous treatment protocols for breast cancer, which remains a leading cause of cancer-related mortality among women, metastasis continues to pose a major challenge during therapy. This results in prolonged treatment durations, poor prognosis, and the need to manage newly emerging cancer types due to the development of secondary tumors. This study aimed to investigate the anti-metastatic effects of miR-640 previously shown to influence tumorigenesis, angiogenesis, inflammatory responses, and metastasis in various cancers, including breast cancer—by examining its potential to downregulate metastasis-associated genes. Materials and Methods: To assess the anti-metastatic potential of miR-640, functional assays—including wound healing, Annexin V, analyses—were conducted following lipofectamine-mediated transfection in MCF7 and MDA-MB-231 breast cancer cell lines. Additionally, expression levels of metastasis-associated genes (WNT7A, TMSB4X, NFIB, ZEB2, IL11, AURKA, CAV1, SLC7A11, PDK1, and PTK6) identified as potential targets of miR-640, were analyzed. Results: Successful transfection was achieved in both cell lines, with a significant increase in miR-640 expression (~25-fold in MCF7, ~5-fold in MDA-MB-231). Statistically significant effects of miR-640 were observed in wound healing and Annexin V assays following transfection. Additionally, gene expression analyses revealed significant reductions in the expression of metastasis-related genes WNT7A, TMSB4X, NFIB, IL11, AURKA, CAV1, SLC7A11, PDK1, PTK6 in the MCF7 cell line, and in WNT7A, NFIB and ZEB2 genes in the MDA-MB-231 cell line. Conclusion: This study is the first to demonstrate that miR-640 exerts an anti-metastatic effect in breast cancer by suppressing metastatic formation through the downregulation of metastasis-related genes. The findings show that cell migration is significantly inhibited in the transfected cell lines and suggest that miR-640 may serve as a potential therapeutic molecule

Keywords

Supporting Institution

This study was supported by the TUSEB (Presidency of Turkish Health Institutes) A GROUP EMERGENCY Research and Development PROJECT SUPPORT PROGRAM No. 35685.

Project Number

35685

Thanks

This study was supported by the TUSEB (Presidency of Turkish Health Institutes) A GROUP EMERGENCY Research and Development PROJECT SUPPORT PROGRAM No. 35685.

References

  1. Avgustinova, A., Iravani, M., Robertson, D., Fearns, A., Gao, Q., Klingbeil, P., … Isacke, C. M. (2016). Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nature Communications 2016 7:1, 7(1), 1–14. doi:10.1038/ncomms10305
  2. Awolaran, O., Brooks, S. A., & Lavender, V. (2016). Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence. Breast (Edinburgh, Scotland), 30, 156–171. doi:10.1016/J.BREAST.2016.09.017
  3. Brasó-Maristany, F., Paré, L., Chic, N., Martínez-Sáez, O., Pascual, T., Mallafré-Larrosa, M., … Prat, A. (2022). Gene expression profiles of breast cancer metastasis according to organ site. Molecular Oncology, 16(1), 69. doi:10.1002/1878-0261.13021
  4. Castanon, I., Von Stetina, S., Kass, J., & Baylies, M. K. (2001). Dimerization partners determine the activity of the Twist bHLH protein during Drosophila mesoderm development. Development, 128(16), 3145–3159. doi:10.1242/DEV.128.16.3145
  5. Cha, S., Lee, E., & Won, H. H. (2021). Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites. Npj Breast Cancer 2021 7:1, 7(1), 1–11. doi:10.1038/s41523-021-00303-y
  6. Chhichholiya, Y., Ruthuparna, M., Velagaleti, H., & Munshi, A. (2023). Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood–brain barrier and treatment strategies. Clinical and Translational Oncology 2023 25:5, 25(5), 1218–1241. doi:10.1007/S12094-022-03050-Z
  7. Coleman, R. E., Smith, P., & Rubens, R. D. (1998). Clinical course and prognostic factors following bone recurrence from breast cancer. British Journal of Cancer 1998 77:2, 77(2), 336–340. doi:10.1038/bjc.1998.52
  8. Friedel, G., Pastorino, U., Ginsberg, R. J., Goldstraw, P., Johnston, M., Pass, H., … Toomes, H. (2002). Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the international registry of lung metastases. European Journal of Cardio-Thoracic Surgery, 22(3), 335–344. doi:10.1016/S1010-7940(02)00331-7

Details

Primary Language

English

Subjects

Cancer Therapy (Excl. Chemotherapy and Radiation Therapy) , Chemotherapy , Molecular Targets , Oncology and Carcinogenesis (Other)

Journal Section

Research Article

Publication Date

March 9, 2026

Submission Date

August 25, 2025

Acceptance Date

September 10, 2025

Published in Issue

Year 1970 Volume: 65 Number: 1

Vancouver
1.İsmail Mert Alkaç, Çığır Biray Avcı. The effect of miR-640 on metastatic genes in breast cancer. EJM. 2026 Mar. 1;65(1):1-10. doi:10.19161/etd.1771783

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.